Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Nice lift by Solena

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Sep 26, 2023 7:53pm

173 Views

Post# 35655912

RE:Nice lift by Solena

We could have similar success - but I'm hoping we get it right on acute and then they provide a direction for chronic ... all in 2024.

If we get that ...

then we go back to all the other goodies that await - like breakthrough therapy designation ???

All depends on P1 and P2 success first - fingers crossed.

: )

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism